Compass Therapeutics (CMPX) Operating Expenses (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Operating Expenses data on file, last reported at $20.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 12.99% year-over-year to $20.3 million; the trailing twelve-month figure through Mar 2026 stood at $75.2 million (up 19.94% YoY), and the FY2025 full-year result was $72.8 million, up 26.73% from the prior year.
• Operating Expenses improved to $20.3 million in Q1 2026, from $18.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $21.1 million in Q2 2025 to a low of $7.2 million in Q1 2022.
• A 5-year average of $14.3 million and a median of $13.3 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 115.2% in 2022 and dropped 5.33% in 2023, its largest moves.
• Tracing CMPX's Operating Expenses over 5 years: stood at $12.9 million in 2022, then advanced by 19.44% to $15.4 million in 2023, then rose by 7.67% to $16.6 million in 2024, then grew by 8.54% to $18.0 million in 2025, then gained by 12.83% to $20.3 million in 2026.
• Business Quant data shows CMPX's Operating Expenses at $20.3 million in Q1 2026, $18.0 million in Q4 2025, and $15.8 million in Q3 2025.